After a slow 2016, with only 22 new molecular entities, new drug approvals picked back up. Here are the ones that made the grade.
Johnson & Johnson is paying $350 million upfront to join forces with Legend as they look for a working “cure” for certain blood cancers.
The impact of protracted contracting timelines can be felt throughout the study start-up process. Coupling predictive enrollment analytics with contract…
Next year will be a busy time for the European Medicines Agency as it looks to complete its move to Amsterdam.
If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.
At the end of the year, we all like to navel gaze, and editors are no different. It's a good time to reflect on what we write about, the importance of…
Will this year’s resurgence be sustained in 2018 in the face of a more uncertain environment?
While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.
The move positions Loxo to wrap up the filing for the Bayer-partnered TRK inhibitor early next year.
Alnylam, which put its hemophilia program on hold in September, has gotten the all-clear from the FDA to resume trials.
Officials want firms to team up to test multiple candidates in single trials, thereby cutting the number of patients who receive placebos.